Introducing a novel approach to targeted protein degradation, biological PROTACs (bioPROTACs) represent a promising alternative to traditional PROTACs. By engineering intracellular proteins fused with target-binding domains and E3 ubiquitin ligases, bioPROTACs offer enhanced specificity and efficacy in degrading challenging targets like KRAS and proliferating cell nuclear antigen (PCNA).

This innovative technology not only provides powerful tools for understanding degradation mechanisms and target biology but also holds significant potential for therapeutic applications, offering new avenues for treating diseases by precisely modulating protein levels and functions.